Category: Life Sciences
Life Sciences market research reports by DelveInsight
-
Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025
“Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Apolipoprotein B (ApoB) Inhibitor development. The report provides detailed coverage of the pipeline ... Read More
-
Caspase 3 (CPP32, Apopain or YAMA) Activators - Pipeline Insight, 2025
“Caspase 3 (CPP32, Apopain or YAMA) Activators - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Caspase 3 (CPP32, Apopain or YAMA) Activators development. The report provides detailed ... Read More
-
Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2025
“Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-17 (IL-17) Inhibitor development. The report provides detailed coverage of the pipeline l ... Read More
-
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Interleukin-18 (IL-18) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products ... Read More
-
Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2025
“Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Murine Double Minute 2 (MDM2) Inhibitor development. The report provides detailed coverage of ... Read More
-
Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2025
“Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Serotonin Reuptake Inhibitor (SRI) development. The report provides detailed coverage of the pipeli ... Read More
-
TGF-Beta-1 Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “TGF-Beta-1 Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in TGF-Beta-1 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ... Read More
-
Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2025
“Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Pot ... Read More
-
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025
DelveInsight’s, “Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Glucagon-Like Peptide 1 Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclin ... Read More
-
Potassium channel antagonists - Pipeline Insight, 2025
DelveInsight’s, “Potassium channel antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Potassium channel antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
Complement C1 inhibitors - Pipeline Insight, 2025
DelveInsight’s, “Complement C1 Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complement C1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
Gaucher's Disease Type III - Pipeline Insight, 2025
DelveInsight’s, “Gaucher’s disease type III - Pipeline Insight, 2025,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Gaucher’s disease type III pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also co ... Read More
-
WHIM Syndrome - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights WHIM syndrome is a rare genetic disorder caused by CXCR4 mutations, leading to immunodeficiency, warts, hypogammaglobulinemia, and myelokathexis. In 2023, the diagnosed prevalent population in the 7MM was estimated to be around 179 individuals. WHIM is a significant health issue in th ... Read More
-
Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights: Irritable bowel syndrome is believed to be a multifactorial disease involving motility dysfunction, visceral hypersensitivity, psychiatric comorbidity, neuroendocrine dysfunction, genetics and epigenetics, diet, and immune activation. Approximately 32 million cases of irritable bowel ... Read More
-
Post-Bariatric Hypoglycemia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the United States accounted for approximately 90% of the total Post-Bariatric hypoglycemia market size within the seven major markets. Post-Bariatric hypoglycemia is the development of hypoglycemia (low blood sugar) following bariatric surgery, such as gastric bypass or sleev ... Read More
-
Allergic Rhinitis - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the Allergic Rhinitis Market Size was highest in the US among the 7MM, accounting for approximately USD 3,600 million which is further expected to increase by 2034. In 2023, the prevalence of Allergic rhinitis was highest in Japan among the 7MM, accounting for approximately 6 ... Read More
-
Gaucher disease Type 1 - Pipeline Insight, 2025
DelveInsight’s, “Gaucher disease Type 1 - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gaucher disease Type 1 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ... Read More
-
Gaucher's disease - Pipeline Insight, 2025
DelveInsight’s, “Gaucher’s Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 14+ companies and 16+ pipeline drugs in Gaucher’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therape ... Read More
-
1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025
“1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 1,3-Beta-Glucan Synthase Inhibitor development. The report provides detailed coverage of the pipeli ... Read More
-
30S Ribosomal Subunit (30S RNA) Inhibitor - Pipeline Insight, 2025
“30S Ribosomal Subunit (30S RNA) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 30S Ribosomal Subunit (30S RNA) Inhibitor development. The report provides detailed coverage ... Read More
-
5-HT1 Antagonist - Pipeline Insight, 2025
“5-HT1 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT1 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ... Read More
-
5-HT1B Antagonist - Pipeline Insight, 2025
“5-HT1B Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT1B Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of ... Read More
-
5-HT4 Agonist - Pipeline Insight, 2025
“5-HT4 Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, ... Read More
-
Adenosine A2 Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A2 Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A2 Receptor Antagonist development. The report provides detailed coverage of the pipeline l ... Read More
-
Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A3 Receptor Antagonist development. The report provides detailed coverage of the pipeline l ... Read More
Research Assistance
